Private Access to $2.4B+ in Early-Stage BioTech Opportunities
An exclusive investment platform for accredited investors seeking breakthrough life-sciences innovation before mainstream capital arrives — early-stage access, curated due diligence, institutional-quality deal flow.
- Direct access to pre-institutional biotech and medtech rounds
- Curated due diligence from a team with FDA and exit experience
- Institutional-quality deal flow across therapeutic areas
Proven track record in life-sciences innovation, quantified across every metric that matters to limited partners.
Portfolio Companies Leading Medical Innovation
Current and exited investments spanning gene therapy, oncology, cardiovascular devices, diagnostics, and digital health.
Our Investment Thesis: Early-Stage Life-Sciences Leadership
Four core pillars drive our biotech and medical-device selection process — positioning our firm as sophisticated life-sciences specialists, not generalist VCs.
Breakthrough Science
We evaluate novel mechanisms of action and first-in-class potential. A gene-editing platform with a differentiated delivery mechanism scores higher than an incremental improvement on an existing therapy — novelty drives long-term value.
Regulatory Pathway
We assess clarity of the FDA roadmap and de-risked approval milestones. A device with an established 510(k) precedent carries far less regulatory risk than a novel PMA pathway — timeline certainty matters for returns.
Market Timing
We weigh unmet medical need against the reimbursement landscape. A diagnostic addressing a payer-recognized gap in early cancer detection has a materially faster path to adoption than one without coverage precedent.
Management Team
We evaluate proven biotech leadership and execution track record. A founding team that has previously guided a therapy through FDA approval carries far greater execution confidence than a first-time founder alone.
Representative Portfolio Outcomes
Series A → Acquisition by Pharma Major
Entered at Series A; company reached pivotal Phase 2 data and was acquired by a top-10 pharmaceutical company.
Pre-FDA → Successful IPO
Entered pre-clearance; company secured FDA approval, scaled commercial distribution, and completed a public offering.
Seed → Series C, Current Appreciation
Entered at seed; platform scaled to a Series C raise with strong current-valuation appreciation and active liquidity path.
Institutional-quality due diligence, curated deal flow, and co-investment access in one platform.
Request Private Access
Dr. Sarah Chen
Dr. Chen holds a PhD in Molecular Biology and spent 15 years leading life-sciences investments at a top-tier venture firm, before which she served as a biotech executive at Johnson & Johnson. She transitioned from pharmaceutical R&D to investing after watching breakthrough therapies struggle to find early-stage funding — a gap she built Meridian BioCapital to close.
She has led investments in three companies that went on to achieve FDA approval and successful exits, and has been featured in BioPharma Dive, Forbes Healthcare, and Nature Biotechnology for her work identifying breakthrough life-sciences opportunities at the earliest stage.
As Featured In Leading Industry Publications
Media recognition across biotech and investment industry coverage reinforces our thought leadership and due-diligence process.
Request Private Investment Access
Qualified accredited investors only. Complete the preliminary assessment below to be considered for platform access, institutional due diligence, and co-investment opportunities.
- Early access to pre-institutional biotech and medtech opportunities
- Institutional-quality due diligence on every opportunity presented
- Co-investment access alongside our own capital
Investment Platform FAQ
Minimum commitments typically range from $100,000 to $250,000 depending on the specific opportunity and vehicle structure. Certain co-investment opportunities may have higher minimums given deal size and syndicate terms. All commitments are subject to accredited investor verification and available capacity within a given round. Exact minimums are disclosed in the offering materials shared after your qualification is confirmed.
Our deal flow comes from a fifteen-year network spanning academic technology transfer offices, biotech operators, FDA regulatory consultants, and co-investment relationships with specialist life-sciences funds. We evaluate over 400 opportunities annually across gene therapy, oncology, cardiovascular devices, diagnostics, and digital health, and typically fund fewer than three percent — the same rigor institutional allocators expect from a specialist life-sciences platform.
Hold periods vary by therapeutic area and stage of entry, but our portfolio has historically returned capital between three and five years from initial investment, whether through acquisition, IPO, or secondary sale. Medical device investments have trended toward the shorter end of that range given clearer regulatory pathways, while novel biologics platforms can extend closer to five to seven years depending on clinical milestones.
Most opportunities are structured as direct co-investments alongside our own capital, typically through a special purpose vehicle or direct equity allocation depending on the underlying company's financing round. Terms, liquidation preferences, and governance rights are disclosed in full in the offering documents provided after qualification. We do not use commingled blind-pool fund structures — every allocator sees the specific company and terms before committing.
Our diligence process evaluates the scientific mechanism with outside clinical advisors, models the regulatory pathway against FDA precedent, assesses the competitive and reimbursement landscape, and conducts reference checks on the management team's execution track record. Every opportunity that reaches investors has cleared all four pillars of our investment thesis, with a written diligence memo made available to qualified allocators prior to commitment.
Under SEC Rule 501 of Regulation D, an accredited investor generally has annual income exceeding $200,000 ($300,000 with a spouse) for the past two years, or a net worth exceeding $1 million excluding primary residence, or holds certain professional certifications. Family offices and institutional entities qualify under separate criteria. After you submit the form above, our team will guide you through formal verification, which is required before any offering materials are shared.